Phase 2 Mesothelioma Trial, Recruiting NCT05930665 Sponsor: Sun Yat-sen University Condition: Mesothelioma
Back to Mesothelioma

Phase 2 Mesothelioma Trial, Recruiting

NCT05930665
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with malignant mesothelioma in the lining of the lungs (confirmed by a tissue test), and surgery to cure it is not an option for you.
  • You are generally well enough to carry out light activity and care for yourself (based on a standard fitness scale scored 0 or 1).
  • You have not previously had any drug treatments (such as chemotherapy or immunotherapy) for your advanced or spread mesothelioma.
  • Your cancer can be measured using scans, following specific guidelines used for this type of mesothelioma.
  • Your blood counts, kidneys, and liver are working well enough to safely take part (confirm with trial site).

Who may not be able to join:

  • Your mesothelioma started in the lining of the abdomen, heart, or testicles (rather than the lungs).
  • You have cancer that has spread to the brain or spinal cord and is currently active and untreated.
  • You have taken certain Chinese herbal medicines or immune-boosting treatments used against cancer within the 14 days before starting the trial.
  • You have a known autoimmune disease that is currently active (a condition where your immune system attacks your own body).
  • You have other serious medical conditions that are not well controlled (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-15322302066

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
1 July 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Objective Response Rate (ORR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov